A fresh viewpoint on drug discovery, pharma, and biotech

Subscribe | Become an author | Author LogIn


Contact us at to request profile updates/corrections. You must be an official company representative to do so (only requests from corporate emails are accepted).

Insilico Medicine


A company dedicated to finding novel solutions for aging and age-related diseases using advances in genomics and big data analysis.

Our mission statement and our pledge to our investors, friends and families: Through excellence in knowledge management, machine learning and bioinformatics, relentless pursuit for new drug, omics and clinical outcomes data, development of reliable in silico drug screening methods, novel validation approaches and strong international partnerships in personalized medicine we strive to find real working solutions to cure and prevent age-related diseases and aging itself.

This mission will be achieved within within the regulatory frameworks as well as the legal and ethical boundaries and by working with the outstanding scientists, academic and medical institutions and pharmaceutical companies of impeccable credibility.

Our goals are:

- to become the first and the largest drug discovery company in aging and age-related diseases;
- to become the first company to fully implement the concept of personalized science, where medicine is developed, tested and validated for individual patients in a safe high-throughput environment

Year Founded
United States of America based
$16.0 M
Field/area focus
Chemistry and Biology
Research papers
Research Use Case
  • Biomarker Discovery
  • Target identification/validation
  • Personalized Medicine
  • Lead Identification
  • Lead optimization
  • Preclinical Experiments
  • Drug Repurposing
  • Data mining, hypothesis generation
Therapeutic focus
  • Dermatology
  • Metabolics
  • Oncology
  • Neuroscience
  • Senescence
Data type
  • EHR
  • omics
Product type
  • small molecules
  • biomarkers
Business model
  • own drug discovery programs
Drug Discovery Strategy
  • Hybrid strategies

Industry Partnerships

2017GSKidentification of novel biological targets and pathways of interest to GSK
2018WuXi AppTecapply next-generation AI to discover the ideal pre-clinical candidates for novel and challenging biological targets, including orphan targets with no known crystal structure and no known ligands

Posts Mentioning This Company

How Big Pharma Adopts AI To Boost Drug Discovery - Oct. 8, 2018
Biopharma Insights
[Interview] The Current Status Of AI In Drug Discovery And Looking Forward Into 2018 - Dec. 26, 2017
Biopharma Insights
Outsourcing AI For Drug Discovery: Independent Expertise Is Key To Avoid Overhyped Claims - Dec. 26, 2017
Featured Research
Navigating In REAL Chemical Space To Find Novel Medicines (Now 3.8 Billion Molecules) - July 27, 2018
New Tools, Products and Technologies
2018 Brings A Surge Of Activity In The “AI For Drug Discovery” Space - March 15, 2018
Biopharma Insights
Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery - Sept. 12, 2018
Biopharma Insights